5-hydroxytryptophan/carbidopa low dose (EVX-101) / Evecxia - LARVOL DELTA

Evecxia Therapeutics Announces Data Presentations on Lead Candidate EVX-101 at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting (Businesswire) - "Evecxia Therapeutics...today announced that an oral presentation, 'The Therapeutic Potential of EVX-101 to Amplify Serotonin Synthesis for the Adjunctive Treatment of MDD and Other Mental Illness: Emerging Profile and Post-Phase 1 Update', will be presented during the Pharmaceutical Pipeline Session on May 30th by Dr. Jacobson, Chief Scientific Officer, at the 2023 ASCP Meeting in Miami Beach, FL....'We are excited to present the Phase 1 data on EVX-101 in combination with a first-line serotonin reuptake inhibitor in healthy volunteers. The data support the use of EVX-101 as a first-choice therapy among next-line antidepressants and could provide a safe and efficacious option for MDD patients not responding to monotherapy with first-line serotonin reuptake inhibitors.'"

P1 data • CNS Disorders • Depression • Major Depressive Disorder